Core Viewpoint - The stock price of药捷安康-B (02617.HK) experienced a significant drop of 45% after previously soaring by 63% and reaching a peak of 679.5 HKD per share, indicating high volatility in the market [1][3]. Company Overview -药捷安康 is a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases. The company has no commercialized products and reported zero revenue with a loss of 123 million HKD in the first half of the year [3][4]. - The company’s market capitalization exceeded 120 billion HKD, having increased over 30 times since its IPO price of 13.15 HKD less than three months ago [3]. Recent Developments - On September 10, the company received clinical trial approval from the National Medical Products Administration of China for its core product, Tinengotinib (TT-00420), in a Phase II trial for treating hormone receptor-positive, HER2-negative metastatic breast cancer [3][4]. - Early clinical results for Tinengotinib show promising effects in patients with HR+/HER2- breast cancer who have undergone multiple treatments, suggesting potential breakthroughs in treatment strategies [4]. Market Context - There are currently no other products in development with the same mechanism as Tinengotinib, although there are competing products in various cancer treatment areas [7]. - The stock's dramatic price fluctuations are attributed to limited market circulation, with only 15.28 million shares available for trading out of a total of 397 million shares [7][9].
刚刚，药捷安康“崩了”：从大涨63%，到暴跌45%